Abstract
Advances in understanding basal ganglia function have suggested several nondopaminergic approaches to the treatment of parkinsonian symptoms. Data from studies in animal models of Parkinson's disease suggest that it is realistic to believe that these approaches might have antiparkinsonian efficacy comparable to those of currently available dopamine-replacing agents and might not be associated with debilitating dyskinetic side-effects after prolonged treatment.
Keywords